Twelve months after revaccination, antibody levels declined but remained significantly higher than baseline in patients with CLL.

with or without Roche's anti-CD20 drug Gazyva (obinutuzumab) – compared to standard therapy in previously untreated adult patients with CLL without del(17p) or TP53 mutations. Patients in the ...

The rationale of this association relies on the capacity of GM-CSF to increase surface expression of CD20 on CLL cells and also to enhance antibody-dependent cellular cytotoxicity against CLL cells.

“The preclinical data suggest that it is more active than rituximab in cells that have a low number of CD20 molecules on the surface, which is characteristic of CLL but probably less important ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Lead programs include CD20-targeting CAR T cells for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), being developed in collaboration with Fred Hutchinson Cancer Research Center ...

Developments in chronic lymphocytic leukemia (CLL) this year included the ... particularly the inclusion of an anti-CD20 monoclonal antibody, as well as mechanisms of resistance and sensitivity ...